Article Sidebar

pdf
Date Published: 16/03/2026
Abstract Views: 47
Views pdf: 24
DOI: https://doi.org/10.51298/vmj.v560i1.17772
Issue
Vol. 560 No. 1 (2026)
Section
Các bài báo
How to Cite
Lê, K. T., & Trương, D. N. A. (2026). PREVALENCE AND CLINICAL CHARACTERISTICS OF HEART FAILURE WITH IMPROVED EJECTION FRACTION AFTER ONE YEAR OF OPTIMAL MEDICAL THERAPY AT TAM DUC HEART HOSPITAL. Vietnam Medical Journal, 560(1). https://doi.org/10.51298/vmj.v560i1.17772

PREVALENCE AND CLINICAL CHARACTERISTICS OF HEART FAILURE WITH IMPROVED EJECTION FRACTION AFTER ONE YEAR OF OPTIMAL MEDICAL THERAPY AT TAM DUC HEART HOSPITAL

Kim Tuyến Lê, Duy Ngọc Anh Trương

Main Article Content

Abstract

Objective: To determine the prevalence and clinical characteristics of heart failure with improved ejection fraction (HFimpEF) in patients with chronic heart failure with reduced ejection fraction after 1 year of treatment. Methods: A retrospective cohort study was conducted on 160 patients with LVEF < 40% treated at Tam Duc Heart Hospital from June 2022 to June 2023. HFimpEF was defined as an increase in LVEF > 10% from baseline and a second LVEF > 40%. Results: The mean age was 59.75 + 14.62 years, 72.5% were male. Usage of guideline-directed medical therapy was high: ACEi/ARB/ARNI (96.9%), Beta-blockers (88.8%), MRAs (86.3%), and SGLT2i (69.4%). After 1 year, 44 patients met HFimpEF criteria (27.5%). The improved group showed significant reduction in LVMI (142 vs 100.5 g/m2 p<0.001) and increase in median LVEF (28% to 54%, p<0.001). Conclusion: The prevalence of HFimpEF was 27.5% with optimal medical therapy. Adherence to multimodal treatment significantly improves cardiac structure and function.

Article Details

Keywords

Heart failure with improved ejection fraction, HFimpEF, LVEF, medical therapy.

References

1. Phạm Nguyễn Vinh, Phạm Mạnh Hùng (2022). Khuyến cáo về chẩn đoán và điều trị bệnh suy tim cấp và suy tim mạn. Hội Tim mạch Quốc gia Việt Nam.
2. Trần Đại Cường, Phạm Dương L, Hoàng Văn S (2024). Khảo sát điều trị suy tim theo khuyến cáo của Hội Tim mạch châu Âu 2021 ở các mức phân suất tống máu khác nhau. Tạp chí Y học Việt Nam, 534(1B).
3. Heidenreich PA, Bozkurt B, Aguilar D, et al (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation, 145(18), e895-e1032.
4. He Y, Ling Y, Guo W, et al (2021). Prevalence and Prognosis of HFimpEF Developed From Patients With Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis. Front Cardiovasc Med, 8, 757596.
5. Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, et al (2016). Characteristics and Outcomes of Adult Outpatients With Heart Failure and Improved or Recovered Ejection Fraction. JAMA Cardiol, 1(5), 510-518.
6. McDonagh TA, Metra M, Adamo M, et al (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J, 42(36), 3599-3726.
7. Savarese G, Vedin O, D'Amario D, et al (2019). Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure. JACC Heart Fail, 7(4), 306-317.
8. Wilcox JE, Fang JC, Margulies KB, Mann DL (2020). Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel. J Am Coll Cardiol, 76(6), 719-734.